Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Profession Professional Development

Carl Zeiss Meditec Invests in Oraya Therapeutics

Oraya Therapeutics Inc., a privately-held company that produces a low-energy, stereotactic radiotherapy instrument, IRay, for the treatment of wet AMD, are to receive funding from Carl Zeiss Meditec (CZM) for “the implementation of its growth strategy over a period of up to two years”, according to a CZM press release (1). In return, CZM will receive share purchase rights – up to a majority stake – after this two-year period. The funding amount has not been divulged, but in discussing the transaction, Ludwin Monz, CZM’s CEO stated: “The current pharmaceutical treatment regimens for wet AMD are exceptionally costly and burdensome, and Oraya’s unique therapy offers a significant potential to positively impact the management of this debilitating disease.”

Clearly, there’s value in the investment for CZM, but to discover what the deal means for Oraya Therapeutics, we spoke to it’s CEO, Jim Taylor.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register